Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Mont...(Diluted $0.53 ...),Health

Date:11/5/2009

Diluted $0.53 $0.87 $1.30 $1.48 ----- ----- ----- ----- Shares used to compute net income per share: Basic 17,089 16,535 16,909 16,336 ------ ------ ------ ------ Diluted 17,965 17,754 17,892 17,616 ------ ------ ------ ------

                                   GENOPTIX, INC.
                        CONDENSED CONSOLIDATED BALANCE SHEETS
                                   (in thousands)

                                               September 30,  December 31,
                                                   2009          2008
                                                   ----          ----
                                                (unaudited)
    Assets
    Current assets:
      Cash and cash equivalents                      $19,865       $38,108
      Short-term investment securities               117,922        64,830
      Accounts receivable, net                        23,529        15,604
      Deferred tax asset                               4,735         4,707
      Other current assets                             2,754         2,179
                                                       -----         -----
    Total current assets                             168,805       125,428
    Property and equipment, net                       12,759        12,189
    Long-term investment security                      3,883         3,775
    Long-term deferred tax asset                       2,347         2,510
    Restricted cash                                      270           360
    Other long-term assets                               350           183
                                                         ---           ---
    Total assets         
'/>"/>
SOURCE  Genoptix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 
Related medicine technology :

1. Genoptix, Inc. Announces Availability of MPL W515 L/K Mutation Analysis for MPD at 49th Annual American Society of Hematology (ASH) Meeting
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Spherix Reports Second Quarter Earnings
4. Tapestry Reports Second Quarter 2007 Results
5. Callisto Reports on Second-Quarter 2007 Milestones
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
9. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
10. Biopure Reports on Meeting with the FDA
11. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors